News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Synteract has added two new executives to support its oncology, neuro degenerative and rare disease centers of development.
Christopher Heckman (image left), RN, BSN, joins as the vice president for oncology development. “From pathway-targeted therapies, to chemotherapy, immunotherapy, and cell-based and gene therapies – Synteract has an impressive track record in operationalizing complex oncology clinical trials,” said Heckman.
He told us he is excited to build on this expertise to advance innovative therapies, adding, “I also look forward to extending our strategic consultative approach to more fully supporting clients across the drug development lifecycle.”
Art Wamil, MD, PhD (image right) joins as senior medical director and lead neurologist.
Wamil, a neurologist/electrophysiologist with more than 20 years of experience, told us he is looking forward to contributing his experience to further strengthen Synteract’s neuro degenerative center of development, “and to encourage collaborative communication across Synteract with sponsors’ teams in the neurology/neuroscience continuum.”
“I am focused on increasing opportunities in the neuro degenerative space that are dominated by innovative and ethical designs, which warrant expedited delivery of results,” he said.
“Synteract is a great company to trust with timely delivery of studies, based on incredible planning capabilities and medical expertise – to start a new wave of development from neuro-degeneration to neuro-regeneration, with the big picture in mind.”